Report of Foreign Issuer (6-k)
27 Diciembre 2018 - 8:43AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of December, 2018
Commission File Number:
001-36000
XTL Biopharmaceuticals Ltd.
(Translation of registrant’s name
into English)
5 Badner St.
Ramat Gan,
4365603, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
RAMAT
GAN, Israel
— (December 27, 2018)
XTL Biopharmaceuticals Ltd. (the
“Company”) announces today the results of the Annual General Meeting of shareholders of the Company, held today, Thursday,
December 27, 2018, in Bnei Brak, Israel (the “Meeting”). At the Meeting, all the proposals set forth in Company’s
announcement dated November 20, 2018 sent in connection with the Meeting were approved by the required majority of shareholders.
The resolutions were as follows:
|
|
1.
|
To approve the re-appointment
of Kesselman & Kesselman, Israel CPAs, a member firm of PricewaterhouseCoopers International Limited, as the Company’s
independent registered public accounting firm for the year ending December 31, 2018 and until our next annual general meeting
of shareholders, and to authorize the Company’s Board of Directors to fix such accounting firm’s annual compensation.
|
|
|
2.
|
To elect Messrs.
Alexander Rabinovitch, Dr. Jonathan Schapiro, Shlomo Shalev, Doron Turgeman and Dr. Dobroslav Melamed to hold office as directors
in the Company, commencing on the date of the Meeting and until the next Annual General Meeting of Shareholders.
|
|
|
3.
|
To approve the employment terms of Mr. Doron Turgeman,
the Chairman of the Board of the Company
.
|
About XTL Biopharmaceuticals Ltd.
(XTL)
XTL Biopharmaceuticals
Ltd., is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune
diseases. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of autoimmune diseases
including systemic lupus erythematosus (SLE) and Sjögren’s Syndrome (SS). The few treatments currently on the market
for these diseases are not effective enough for most patients and some have significant side effects. hCDR1 has robust clinical
data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer
reviewed scientific journals.
XTL is traded
on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following
indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals
Ltd.
Tel: +972 3 611 6666
Email: ir@xtlbio.com
www.xtlbio.com
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
XTL BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
Date: December 27, 2018
|
By:
|
/s/ Josh Levine
|
|
|
|
Josh Levine
|
|
|
|
Chief Executive Officer
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
